Phase 1: full-text search runs
Every question run against AY25-26 events with BM25 (pages + speaker notes, objectives, event title/description), without and with MeSH expansion. Generated by scripts/phase1_baseline.py.
Q01: Where do students learn the mechanisms of heart failure with reduced vs preserved ejection fraction?
Query heart failure reduced preserved ejection fraction · scope PCV AY25-26 · gold Heart Failure & Cardiomyopathy, Principles of Heart Failure Treatment, Week 5: Prework · recall@10 3/3
MeSH expansion added: Right Sided Heart Failure, Left Sided Heart Failure, Congestive Heart Failure, Left-Sided Heart Failure, Cardiac Failure, Hearts, Right-Sided Heart Failure, Myocardial Failure, Heart Decompensation
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.89 | PCV | FCB | 5 | Heart Failure & Cardiomyopathy - FCB | Lecture | 1 | 1 | 0.89 | FCB-PCV-Heart Failure and Cardiomyopathy-FA25-AC-FINAL.pptx |
| 2.8 | PCV | AMC | 5 | Heart Failure & Cardiomyopathy - AMC | Case-Based Instruction/Learning | 0.8 | 1 | 1 | Heart Failure and Cardiomyopathy - FINAL 2025.pptx |
| 2.6 | PCV | FCB | 6 | Principles of Heart Failure Treatment - FCB | Lecture | 0.96 | 0.7 | 0.95 | 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf |
| 2.4 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0.77 | 0.7 | 0.93 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 2.08 | PCV | AMC | 6 | PCV Clinical Cases: Heart and Respiratory Failure - AMC | Case-Based Instruction/Learning | 0.89 | 0.54 | 0.65 | FINAL PCV Cases Heart and Resp Failure Week 6 2025 - with answers, release AFTER.pptx |
| 2.07 | PCV | FCB | 6 | Pathology Lab: Heart Failure and Cardiomyopathy - FCB | Laboratory | 0.92 | 0.58 | 0.57 | 6-00645-Cardiomyopathy Pathology_CONTENT_GCA_25.pdf |
| 1.8 | PCV | AMC | 6 | Pathology Lab: Heart Failure and Cardiomyopathy - AMC | Laboratory | 0.79 | 0.58 | 0.43 | AFTER_Heart Failure and Cardiomyopathy answers.pdf |
| 1.78 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 0.82 | 0.97 | PCV Heart failure prework w audio.pptx |
| 1.42 | PCV | FCB | 6 | PCV Clinical Cases: Heart and Respiratory Failure - FCB | Lecture | 0.89 | 0.54 | 0 | nan |
| 1.41 | PCV | nan | 6 | PCV Clinical Cases: Heart and Respiratory Failure | nan | 0.88 | 0.54 | 0 | nan |
- PCV wk5 Heart Failure & Cardiomyopathy - AMC — Heart Failure and Cardiomyopathy - FINAL 2025.pptx p.13: | # Heart Failure Basic Principles Heart Failure We think differently about: Left vs right heart failure Preserved vs reduced ejection fraction Left sided Right sided
Prese - PCV wk5 PCV Week 5: Prework - AMC — PCV Heart failure prework w audio.pptx p.13: | # Introduction to Heart Failure Heart Failure Please read this chapter from Lilly’s Pathophysiology of Heart Disease which gives a good foundation for our discussion on types of heart failure this
- PCV wk6 Principles of Heart Failure Treatment - FCB — 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf p.12: | 2 Heart failure ejection fraction: Reduced vs preserved
Q02: Where is HFrEF pharmacotherapy (guideline-directed therapy including SGLT2 inhibitors) taught?
Query HFrEF SGLT2 inhibitor · scope all courses AY25-26 · gold Principles of Heart Failure Treatment · recall@10 1/1
MeSH expansion added: Gliflozin, SGLT 2 Inhibitor, Sodium-Glucose Transporter 2 Inhibitor, Sodium Glucose Transporter 2 Inhibitors, Gliflozins, SGLT-2 Inhibitors, SGLT 2 Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Sodium Glucose Transporter 2 Inhibitor, SGLT2 Inhibitors, SGLT-2 Inhibitor
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2 | PCV | FCB | 6 | Principles of Heart Failure Treatment - FCB | Lecture | 0 | 1 | 1 | 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf |
| 1.95 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0 | 1 | 0.95 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 1.12 | MSI | AMC | 3 | Intro to Rheumatology & Arthritis - Osteoarthritis and Rheumatoid Arthritis - AMC | Large Group | 0 | 0.82 | 0.31 | FINAL_BEFORE_Rheumatology for MSI - Arthritis Part 1_2_2_26.pptx |
| 1.12 | MSI | FCB | 3 | Intro to Rheumatology & Arthritis - Osteoarthritis and Rheumatoid Arthritis - FCB | Lecture | 0 | 0.82 | 0.31 | FINAL_BEFORE_FCB Rheumatology for MSI - Arthritis Part 1_2_2_26.pptx |
| 0.97 | FP | AMC | 5 | Principles of Synaptic Pharmacology - AMC | Lecture | 0 | 0.67 | 0.3 | Final_Before_SynapticPharm_06272025.pptx |
| 0.96 | PCV | FCB | 3 | Atherosclerosis, Lipids & Antilipemic Pharmacology - FCB | Lecture | 0 | 0.64 | 0.32 | 3-00270-Atherosclerosis & Antilipemics_CONTENT_GCA_25.pdf |
| 0.95 | FP | FCB | 3 | The Complement System - FCB | Lecture | 0 | 0.7 | 0.26 | SLIDE DECK. 081224_The Complement System_BEFORE CLASS_FINAL (1).pptx |
| 0.93 | FP | AMC | 3 | The Complement System - AMC | Large Group | 0 | 0.7 | 0.23 | SLIDE DECK. 081425_Complement System_FINAL_BEFORE CLASS.pptx |
| 0.92 | FP | FCB | 5 | Principles of Synaptic Pharmacology - FCB | Lecture | 0 | 0.67 | 0.26 | 5-00600-Principles of Synaptic Pharmacology_CONTENT_GCA_25.pdf |
| 0.87 | PCV | AMC | 3 | Atherosclerosis, Lipids & Antilipemic Pharmacology - AMC | Large Group | 0 | 0.64 | 0.23 | FINAL 2025 Lipids and Anti-lipidemic Pharmacology 2024.pptx |
- PCV wk6 Principles of Heart Failure Treatment - FCB — 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25.pdf p.70: | C Case 7: SGLT2 inhibitor in chronic heart failure A 64-year-old with chronic HFrEF and type 2 diabetes is started on empagliflozin. Why it matters clinically: SGLT2 inhibitors reduce hospitalizati
- PCV wk
Principles of Heart Failure Treatment - FCB — 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf p.70: | C Case 7: SGLT2 inhibitor in chronic heart failure A 64-year-old with chronic HFrEF and type 2 diabetes is started on empagliflozin. Why it matters clinically: SGLT2 inhibitors reduce hospitalizati - PCV wk6 Principles of Heart Failure Treatment - AMC — Principles of Heart Failure Treatment - 2025 FINAL.pptx p.31: | # Goals of therapy: Live longer, feel better | Heart failure with reduced ejection fraction | Heart failure with preserved ejection fraction | | — | — | | Mortality and symptom benefit: β-block
Q03: Where is the ECG introduced and where is it revisited?
Query ECG · scope PCV AY25-26 · gold Cardiac Conduction & ECG Intro, ECG Cases: Cardiac Dysrhythmias, ECG Cases: Chest Pain, Clinical Cases: ABG · recall@10 4/4
MeSH expansion added: Electrocardiograms, Electrocardiograph, 12-Lead ECG, 12 Lead EKG, 12-Lead ECGs, EKG, 12-Lead Electrocardiography, 12 Lead Electrocardiography, Electrocardiogram, 12 Lead ECG, 12-Lead EKGs
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.76 | PCV | FCB | 1 | Cardiac Conduction & ECG Intro - FCB | Lecture | 1 | 0.81 | 0.95 | 1-00060-Cardiac Conduction & ECG Intro_CONTENT_GCA_25.pdf |
| 2.52 | PCV | AMC | 1 | Cardiac Conduction & ECG Intro - AMC | Lecture | 0.71 | 0.81 | 1 | Cardiac conduction and ECG intro 2025 FINAL.pptx |
| 2.46 | PCV | AMC | 3 | ECG Cases: Chest Pain and Ischemia - AMC | Case-Based Instruction/Learning | 0.88 | 0.74 | 0.84 | Ischemia ECG cases with answers - FINAL, release AFTER1.pptx |
| 2.33 | PCV | AMC | 1 | PCV Clinical Cases: ABG, PFT, ECG - AMC | Case-Based Instruction/Learning | 0.65 | 0.85 | 0.82 | Clinical Cases ABG-PFT-ECG 2025 - release to students AFTER event.pptx |
| 2.19 | PCV | AMC | 2 | ECG Cases: Cardiac Dysrhythmias - AMC | Case-Based Instruction/Learning | 0.71 | 0.66 | 0.82 | Cardiac Dysrhythmias Clin Cases 2025 Student version.pptx |
| 2.16 | PCV | AMC | 3 | Acute Coronary Syndromes - Diagnosis & Management - AMC | Large Group | 0.45 | 0.78 | 0.94 | Acute Coronary Syndromes Part 1 Bricker - Diagnosis 2025.pptx |
| 1.87 | PCV | AMC | 2 | PCV Week 2: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.87 | ecg slide deck.pptx |
| 1.78 | PCV | FCB | 1 | PCV Clinical Cases: ABG, PFT, ECG - FCB | Lecture | 0.92 | 0.85 | 0 | nan |
| 1.78 | PCV | AMC | 1 | PCV Week 1: Prework - AMC | Directed Independent Learning | 0 | 0.88 | 0.9 | CV Week 1 Prework 3 of 3 - Intro to ECG.pptx |
| 1.7 | PCV | FCB | 3 | ECG Cases: Chest Pain and Ischemia - FCB | Lecture | 0.96 | 0.74 | 0 | nan |
- PCV wk3 Ischemia, Angina & Claudication - AMC — M1 Event material for ischemia, angina, claudication 2025 FINAL.pptx p.82: | # Coronary Vasospasm
61 year-old female with multiple sclerosis is admitted for urosepsis. A norepinephrine infusion is started to maintain blood p - PCV wk1 Cardiac Conduction & ECG Intro - AMC — Cardiac conduction and ECG intro 2025 FINAL.pptx p.77: | FYI Slide! # 12 lead ECG : lead groupings
, and third-degree AV blocks, including characteristic ECG findings. 5. Bundle Branch Blo
Q04: Where are antiarrhythmic drug classes taught?
Query antiarrhythmic drugs · scope PCV AY25-26 · gold Pharmacology of Antidysrhythmics · recall@10 1/1
MeSH expansion added: Pharmaceuticals, Pharmaceutical Preparation, Anti Arrhythmia Drugs, Anti-Arrhythmia Drug, Antiarrhythmia Agent, Pharmaceutical Preparations, Anti Arrhythmia Agents, Antiarrhythmia Drug, Pharmaceutical, Anti-Arrhythmia Agents
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 1.43 | PCV | FCB | 2 | Autonomic Regulation of the Cardiovascular System - FCB | Lecture | 0 | 1 | 0.43 | 2-00145-Autonomic CV Regulation_CONTENT_GCA_25.pdf |
| 1 | PCV | AMC | 2 | Autonomic Regulation of the Cardiovascular System - AMC | Lecture | 0 | 1 | 0 | nan |
| 1 | PCV | AMC | 2 | Pharmacology of Antidysrhythmics - AMC | Lecture | 0 | 0 | 1 | Zuckerman Rague Antidysrythmic 2025 FINAL.pptx |
| 0.99 | PCV | AMC | 2 | PCV Week 2: Prework - AMC | Directed Independent Learning | 0 | 0 | 0.99 | CV Week 2 Prework - AP, Arrhytmia, and Drug Intro w Audio.pptx |
| 0.99 | PCV | FCB | 2 | Pharmacology of Antidysrhythmics - FCB | Lecture | 0 | 0 | 0.99 | 2-00180-Pharmacology of Antiarrhythmic Drugs_CONTENT_GCA_25.pdf |
| 0.86 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0 | 0.62 | 0.24 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 0.85 | PCV | FCB | 6 | Principles of Heart Failure Treatment - FCB | Lecture | 0 | 0.62 | 0.23 | 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf |
| 0.8 | PCV | FCB | 1 | Action Potentials and Conduction - FCB | Lecture | 0 | 0 | 0.8 | 1-00050-Action Potentials & Conduction_CONTENT_GCA_25.pdf |
| 0.71 | PCV | FCB | 2 | Overview of Dysrhythmias - FCB | Lecture | 0 | 0 | 0.71 | 2-00175-Abnormal Cardiac Electrophysiology_CONTENT_GCA_25.pdf |
| 0.58 | PCV | AMC | 3 | Acute Coronary Syndromes - Diagnosis & Management - AMC | Large Group | 0 | 0 | 0.58 | Acute Coronary Syndromes Part 2 Bricker - Complications and Management 2025.pptx |
- PCV wk2 Pharmacology of Antidysrhythmics - AMC — Zuckerman Rague Antidysrythmic 2025 FINAL.pptx p.18: | # Antiarrhythmics : overview
 of diagnosis of breathing disorders. In patients with respiratory failure, the type of respiratory
- PCV wk1 Blood Gas Analysis: Gas Exchange & Respiratory Failure - FCB — 1-00030-Blood Gas Analysis_CONTENT_GCA_25-26.pdf p.4: | LO Learning Objectives • LO1: Discuss the Henderson-Hasselbalch Equation for Bicarbonate/CO2. • LO2: Discuss the determinants of minute and alveolar ventilation and how they affect CO2 removal. • L
- PCV wk1 Pulmonary + Systemic Circulation - AMC — Circulation talk 2025.pptx p.11: |
# Steps in the Pulmonary Circulation Arteries Carry deoxygenated blood from the right ventricle of the heart to the lungs. Capillary network Gas exchange Veins Carry oxyg
Q06: Where is spirometry and flow-volume loop interpretation taught?
Query spirometry flow volume loop · scope PCV AY25-26 · gold Pulmonary Function Testing · recall@10 1/1
MeSH expansion added: Spirometries
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.49 | PCV | AMC | 4 | PCV Clinical Cases: Cardiac Physiology - AMC | Case-Based Instruction/Learning | 1 | 1 | 0.49 | FINAL Cardiac Phys clinical cases answers version 2025 - release after session.pptx |
| 2.05 | PCV | AMC | 1 | Pulmonary Function Testing - AMC | Lecture | 0.49 | 0.56 | 1 | PCV PFTs Release AFTER lecture.pptx |
| 1.79 | PCV | FCB | 1 | Lung Mechanics - FCB | Lecture | 0 | 0.95 | 0.84 | 1-00015-Lung Mechanics_CONTENT_GCA_25.pdf |
| 1.77 | PCV | AMC | 1 | The Cardiac Cycle - AMC | Lecture | 0.61 | 0.6 | 0.56 | Cardiac Cycle 2025 FINAL.pptx |
| 1.59 | PCV | AMC | 1 | PCV Week 1: Prework - AMC | Directed Independent Learning | 0 | 0.94 | 0.65 | CV Week 1 Prework 1 of 3 - Intro to CV Phys.pptx |
| 1.55 | PCV | FCB | 1 | Pulmonary Function Testing - FCB | Lecture | 0 | 0.56 | 0.99 | 1-00025-Pulmonary Function Tests_CONTENT_GCA_25.pdf |
| 1.4 | PCV | AMC | 1 | Lung Mechanics - AMC | Case-Based Instruction/Learning | 0 | 0.95 | 0.45 | Lung Mechanics Slides -2025 - FINAL.pptx |
| 1.33 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 0.85 | 0.48 | PCV Heart failure prework w audio.pptx |
| 1.14 | PCV | FCB | 1 | Pulmonary + Systemic Circulation - FCB | Lecture | 0 | 0.62 | 0.52 | FCB-PCV-Circulatory Physiology-FA25-AC.pptx |
| 1.13 | PCV | FCB | 1 | The Cardiac Cycle - FCB | Lecture | 0 | 0.6 | 0.53 | FCB-PCV-Cardiac cycle-FA25-AC.pptx |
- PCV wk1 Pulmonary Function Testing - AMC — PCV PFTs Make available BEFORE lecture.pptx p.29: |
Spirometry | Flow-volume loop Peak Flow Depicts airflow vs volume Uses: Helpful in identifying patterns of disease Can identify large airway obstruction (i.e. in the trac - PCV wk1 Pulmonary Function Testing - AMC — PCV PFTs Release AFTER lecture.pptx p.32: |
Spirometry | Flow-volume loop Peak Flow Depicts airflow vs volume Uses: Helpful in identifying patterns of disease Can identify large airway obstruction (i.e. in the trac - PCV wk1 Pulmonary Function Testing - FCB — 1-00025-Pulmonary Function Tests_CONTENT_GCA_25.pdf p.40: | Q’s Question A 62-year-old individual with progressive hoarseness is referred for pulmonary function testing. The flow- volume loop demonstrates flattening of both the inspiratory and expiratory li
Q07: Where is the Frank-Starling mechanism taught?
Query Frank-Starling · scope PCV AY25-26 · gold The Cardiac Cycle, Cardiac and Smooth Muscle Physiology, Week 1: Prework · recall@10 3/3
MeSH expansion added: Mynahs, Oxpeckers, Oxpecker, Starlings, Sturnidae, Mynah
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 1.79 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.79 | PCV Heart failure prework w audio.pptx |
| 1.79 | PCV | FCB | 1 | Cardiac and Smooth Muscle Physiology - FCB | Lecture | 0 | 0.86 | 0.93 | 1-00055-Cardiac & Smooth Muscle Physiology_CONTENT_GCA_25.pdf |
| 1.36 | PCV | AMC | 1 | Cardiac and Smooth Muscle Physiology - AMC | Lecture | 0 | 0.86 | 0.5 | FINAL Cardiac and Smooth Muscle 2025 - FINAL.pptx |
| 1.23 | PCV | AMC | 1 | Pulmonary + Systemic Circulation - AMC | Lecture | 0 | 0.91 | 0.32 | Circulation talk 2025.pptx |
| 1.1 | PCV | FCB | 1 | Pulmonary + Systemic Circulation - FCB | Lecture | 0 | 0.91 | 0.19 | FCB-PCV-Circulatory Physiology-FA25-AC.pptx |
| 1 | PCV | FCB | 5 | PCV Week 5: Prework - FCB | Directed Independent Learning | 0 | 1 | 0 | nan |
| 1 | PCV | AMC | 6 | PCV Clinical Cases: Heart and Respiratory Failure - AMC | Case-Based Instruction/Learning | 0 | 0 | 1 | FINAL PCV Cases Heart and Resp Failure Week 6 2025 - student version, release BEFORE.pptx |
| 0.99 | PCV | AMC | 1 | The Cardiac Cycle - AMC | Lecture | 0 | 0 | 0.99 | Cardiac Cycle 2025 FINAL.pptx |
| 0.86 | PCV | FCB | 1 | The Cardiac Cycle - FCB | Lecture | 0 | 0 | 0.86 | FCB-PCV-Cardiac cycle-FA25-AC.pptx |
| 0.74 | PCV | AMC | 1 | PCV Week 1: Prework - AMC | Directed Independent Learning | 0 | 0 | 0.74 | CV Week 1 Prework 1 of 3 - Intro to CV Phys.pptx |
- PCV wk6 PCV Clinical Cases: Heart and Respiratory Failure - AMC — FINAL PCV Cases Heart and Resp Failure Week 6 2025 - student version, release BEFORE.pptx p.17: | # 3B. Draw a normal Frank-Starling curve and what you think this patient’s curve looks like. How would the treatments affect the Frank-Starling curve?
- PCV wk6 PCV Clinical Cases: Heart and Respiratory Failure - AMC — FINAL PCV Cases Heart and Resp Failure Week 6 2025 - with answers, release AFTER.pptx p.25: | # 3B. Draw a normal Frank-Starling curve and what you think this patient’s curve looks like. How would the treatments affect the Frank-Starling curve?
- PCV wk1 The Cardiac Cycle - AMC — Cardiac Cycle 2025 FINAL.pptx p.46: | # Inotropy and Frank-Starling curves
Decreased inotropy shifts the Frank-Starling curve downward (lower slope) Result: For a given preload, SV will be lower Increased ino
Q08: Where is tuberculosis diagnosis and treatment covered?
Query tuberculosis · scope all courses AY25-26 · gold Tuberculosis, Immunocompromised · recall@10 1/2 · missed Immunocompromised
MeSH expansion added: Koch Disease, Kochs Disease, Mycobacterium tuberculosis Infection, Mycobacterium tuberculosis Infections, Tuberculoses, Koch’s Disease
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.9 | PCV | FCB | 5 | Tuberculosis - FCB | Lecture | 1 | 0.95 | 0.96 | Tuberculosis (2025) - posted.pptx |
| 2.54 | PCV | AMC | 5 | Tuberculosis - AMC | Lecture | 0.62 | 0.95 | 0.97 | tuberculosis 2025.pptx |
| 1.67 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.67 | PCV CT Chest Prework w audio.pptx |
| 1.58 | FP | FCB | 2 | Microbiology & Inflammation: Host-Pathogen Interaction - FCB | Lecture | 0 | 0.9 | 0.68 | Microbiology Inflammation. Host Pathogen Interaction - 2025.pptx |
| 1.57 | FP | AMC | 2 | Microbiology & Inflammation: Host-Pathogen Interaction - AMC | Large Group | 0 | 0.9 | 0.67 | SLIDE DECK. 080725_Integration. Host Pathogen_FINAL_BEFORE CLASS.pptx |
| 1 | PCV | FCB | 5 | PCV Week 5: Prework - FCB | Directed Independent Learning | 0 | 1 | 0 | nan |
| 1 | FP | AMC | 2 | Bacterial Structure, Function & Pathogenesis - AMC | Lecture | 0 | 0 | 1 | Micro2 - Bacterial Structure-function-pathogenesis updated.pptx |
| 0.97 | FP | FCB | 3 | Histopathology of Tissue Injury & Wound Healing - FCB | Lecture | 0 | 0 | 0.97 | FCB_FP_Histopathology of Tissue Injury & Wound Healing_NK.pptx |
| 0.93 | PCV | AMC | 4 | Immunology: Pulmonary Host Defense - AMC | Large Group | 0 | 0 | 0.93 | PCV. Pulmonary Host Defense 2025_before class_FINAL.pptx |
| 0.91 | FP | AMC | 3 | Histopathology of Tissue Injury & Wound Healing - AMC | Lecture | 0 | 0 | 0.91 | FINAL_BEFORE_Week 3 Histopathology of Tissue Injury and Wound Healing student version.pptx |
- FP wk2 Bacterial Structure, Function & Pathogenesis - AMC — Micro2 - Bacterial Structure-function-pathogenesis updated.pptx p.18: | # Mycobacteria Mycobacterium tuberculosis (causes tuberculosis) Mycobacterium leprae (leprosy) Mycobacterium bovis (bovine tuberculosis) Mycobacterium avium complex (chronic lung disease; dissemina
- FP wk2 Bacterial Structure, Function & Pathogenesis - AMC — Micro2 - Bacterial Structure-function-pathogenesis.pptx p.18: | # Mycobacteria Mycobacterium tuberculosis (causes tuberculosis) Mycobacterium leprae (leprosy) Mycobacterium bovis (bovine tuberculosis) Mycobacterium avium complex (chronic lung disease; dissemina
- FP wk3 Histopathology of Tissue Injury & Wound Healing - FCB — FCB_FP_Histopathology of Tissue Injury & Wound Healing_NK.pptx p.11: | 
- PCV wk1 The Cardiac Cycle - AMC — Cardiac Cycle 2025 FINAL.pptx p.23: |

- PCV wk3 Ischemia, Angina & Claudication - FCB — 3-00265-Ischemia, Angina & Claudication_CONTENT_GCA_25.pdf p.47: | Q’s Question A 63-year-old patient with hypertension and diabetes presents with calf pain after walking one block that resolves with rest. Physical examination shows diminished femoral and pedal pu
Q17: Where is the mechanism of action of statins taught?
Query statin HMG-CoA reductase · scope all courses AY25-26 · gold Atherosclerosis, Lipids & Antilipemic · recall@10 1/1
MeSH expansion added: Hydroxymethylglutaryl CoA Reductase Inhibitors, Hydroxymethylglutaryl CoA Reductases, Statins, 3 Hydroxy 3 methylglutaryl CoA Reductase, Oxidoreductase, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitor, CoASH, Hydroxymethylglutaryl CoA Reductase, Hydroxymethylglutaryl-CoA Reductase Inhibitor, HMG-CoA Statins
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2 | PCV | AMC | 3 | Atherosclerosis, Lipids & Antilipemic Pharmacology - AMC | Large Group | 0 | 1 | 1 | FINAL 2025 Lipids and Anti-lipidemic Pharmacology 2024.pptx |
| 1.8 | PCV | FCB | 3 | Atherosclerosis, Lipids & Antilipemic Pharmacology - FCB | Lecture | 0 | 1 | 0.8 | 3-00270-Atherosclerosis & Antilipemics_CONTENT_GCA_25.pdf |
| 1.4 | PCV | AMC | 3 | PCV Week 3: Prework - AMC | Directed Independent Learning | 0 | 0.8 | 0.6 | 0 - Lipids Pre-Work Handout_Trek 2022.docx |
| 0.8 | PCV | FCB | 3 | PCV Week 3: Prework - FCB | Directed Independent Learning | 0 | 0.8 | 0 | nan |
| 0.5 | PCV | FCB | 3 | Ischemia, Angina & Claudication - FCB | Lecture | 0 | 0 | 0.5 | 3-00265-Ischemia, Angina & Claudication_CONTENT_GCA_25.pdf |
| 0.47 | EM | nan | 1 | Pathophysiology of Type 1 Diabetes | Lecture | 0 | 0 | 0.47 | PathophysT1DM2026INSTRUCTORDONOTPOSTFORSTUDENTSfinal.pptx |
| 0.29 | FP | FCB | 4 | Normal and Cancer Cell Metabolism - FCB | Lecture | 0 | 0 | 0.29 | FCB_FP_Normal and Cancer Metabolism.pptx |
| 0.28 | FP | AMC | 4 | Normal and Cancer Cell Metabolism - AMC | Lecture | 0 | 0 | 0.28 | Normal and Cancer Cell Metabolism_Slater2025.pptx |
| 0.22 | RLC | FCB | 1 | Differences in Sexual Development - FCB | Lecture | 0 | 0 | 0.22 | FCB-RLC-Differences in Sexual Development-Slides.pptx |
| 0.22 | RLC | AMC | 1 | Normal Embryology: Development & Differentiation of the Reproductive System - AMC | Lecture | 0 | 0 | 0.22 | Trek Repro Life Cycle Development Differentiation of Reproductive System DRAFT MAY 2026.reviewed.pptx |
- PCV wk3 Atherosclerosis, Lipids & Antilipemic Pharmacology - AMC — FINAL 2025 Lipids and Anti-lipidemic Pharmacology 2024.pptx p.30: | # Statins = HMG CoA Reductase Inhibitors Mechanism of Action: Inhibit HMG CoA reductase Decrease hepatic pool of free cholesterol Increase expression of LDL receptors on cell membranes Increase cat
- PCV wk3 Atherosclerosis, Lipids & Antilipemic Pharmacology - FCB — 3-00270-Atherosclerosis & Antilipemics_CONTENT_GCA_25.pdf p.25: | 1 2 4 Statins: HMG-CoA inhibitors
- PCV wk3 PCV Week 3: Prework - AMC — 0 - Lipids Pre-Work Handout_Trek 2022.docx p.9: | tropical vegetable oils and nuts; and limits intake of sweets, sugar-sweetened beverages, processed foods and red meats. Also recommended is for adults to engage in aerobic physical activity incorp
Q18: Where is the systematic approach to reading a chest X-ray taught?
Query chest radiograph systematic approach · scope PCV AY25-26 · gold Introduction to Chest Radiography · recall@10 1/1
MeSH expansion added: Thorax, Thoraces, Chests, Thorace
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 3 | PCV | AMC | 2 | Introduction to Chest Radiography - AMC | Lecture | 1 | 1 | 1 | IntroChestXRAY 25-26 - FINAL.pptx |
| 2.36 | PCV | FCB | 2 | Introduction to Chest Radiography - FCB | Lecture | 0.36 | 1 | 1 | IntroChestXRAY 25-26 - FINAL.pptx |
| 1.48 | PCV | AMC | 3 | PCV Week 3: Chief Concern - AMC | Lecture | 0.43 | 0.5 | 0.55 | Week 3 Chief Concern - 2025 - FINAL - Chest Pain Release AFTER.pptx |
| 1.31 | PCV | AMC | 2 | PCV Week 2: Prework - AMC | Directed Independent Learning | 0 | 0.38 | 0.93 | Fundamentals of Chest Radiography.pdf |
| 1.24 | PCV | AMC | 5 | PCV Clinical Cases: Radiology, Malignancy, and Hemoptysis - AMC | Case-Based Instruction/Learning | 0.27 | 0.29 | 0.68 | Clinical Cases - Radiology, malignancy, hemoptysis, immune Teachers Guide and post session distribution.docx |
| 1.15 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0.3 | 0.36 | 0.49 | PCV CT Chest Prework w audio.pptx |
| 1.09 | PCV | FCB | 3 | PCV Week 3: Chief Concern - FCB | Large Group | 0 | 0.5 | 0.59 | Chief Concern - FINAL PCV week 3 Faculty version - delayed release.pptx |
| 0.87 | PCV | AMC | 3 | ECG Cases: Chest Pain and Ischemia - AMC | Case-Based Instruction/Learning | 0.31 | 0.23 | 0.33 | Ischemia ECG cases with answers - FINAL, release AFTER1.pptx |
| 0.86 | PCV | AMC | 4 | PCV Week 4: Chief Concern - AMC | Lecture | 0.18 | 0.21 | 0.47 | Week 4 Chief Concern 2025 - FINAL.pptx |
| 0.83 | PCV | FCB | 5 | Pulmonary Considerations of Immunocompromised Patients - FCB | Lecture | 0 | 0.24 | 0.59 | Pulmonary Infections in the Immunocompromised Host Dec 2025 FINAL.pptx |
- PCV wk2 Introduction to Chest Radiography - AMC — IntroChestXRAY 25-26 - FINAL.pptx p.3: | # Learning Objectives Employ a systematic search pattern for interpreting chest x-rays; “how to read a chest radiograph.” Understand penetration, inflation, and rotation on chest X-rays and how the
- PCV wk2 PCV Week 2: Prework - AMC — Fundamentals of Chest Radiography.pdf p.10: | Radiography version 04.21.18 Lavelle A systematic approach A systematic approach to the interpretation of chest radiography findings ensures that we don’t forget anything in the interpretation. One
- PCV wk5 PCV Clinical Cases: Radiology, Malignancy, and Hemoptysis - AMC — Clinical Cases - Radiology, malignancy, hemoptysis, immune Teachers Guide and post session distribution.docx p.11: | FH: Adopted What is your initial differential diagnosis of his hemoptysis? See Algorithm above What testing would you like to evaluate the cause of his hemoptysis? CT of the chest would be the test
Q19: Where is anticoagulation first introduced and where is it revisited?
Query anticoagulant heparin warfarin · scope all courses AY25-26 · gold Anticoagulants, Antiplatelets · recall@10 1/1
MeSH expansion added: Anticoagulant Drugs, Warfarin Sodium, Tedicumar, Liquaemin, Gen-Warfarin, Aldocumar, Anticoagulant Drug, Anticoagulation Agents, Anticoagulant Agents, Heparin Sodium, 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.92 | PCV | AMC | 3 | Anticoagulants, Antiplatelets & Thrombolytics - AMC | Lecture | 1 | 0.92 | 1 | Zuckerman Final AFTER Anticoagulants Antiplateletes Thrombolytics v10032025.pptx |
| 2.74 | PCV | FCB | 3 | Anticoagulants, Antiplatelets & Thrombolytics - FCB | Lecture | 0.99 | 0.92 | 0.83 | 3-00290-Anticoagulants, Antiplatelets_CONTENT_GCA_25.pdf |
| 1.87 | FP | FCB | 1 | Case-Based Review: Pharmacogenetics - FCB | Case-Based Instruction/Learning | 0 | 1 | 0.87 | 1-00085-Case-Based Pharmacogenetics_CONTENT_GCA_25.pdf |
| 1.71 | FP | AMC | 1 | Case-Based Review: Pharmacogenetics - AMC | Lecture | 0 | 1 | 0.71 | Draft_Before_Pharmacogenomics_Zuckerman_06132025.pptx |
| 0.88 | PCV | AMC | 3 | Ischemia, Angina & Claudication - AMC | Case-Based Instruction/Learning | 0 | 0 | 0.88 | M1 Event material for ischemia, angina, claudication 2025 FINAL.pptx |
| 0.71 | PCV | AMC | 6 | Pulmonary Vascular Disease - AMC | Lecture | 0 | 0 | 0.71 | Pulmonary Vascular Disease 2025.pptx |
| 0.65 | PCV | AMC | 3 | ECG Cases: Chest Pain and Ischemia - AMC | Case-Based Instruction/Learning | 0 | 0 | 0.65 | Ischemia ECG cases student - FINAL, release BEFORE1.pptx |
| 0.65 | PCV | AMC | 3 | Acute Coronary Syndromes - Diagnosis & Management - AMC | Large Group | 0 | 0 | 0.65 | Acute Coronary Syndromes Part 2 Bricker - Complications and Management 2025.pptx |
| 0.59 | PCV | FCB | 3 | Ischemia, Angina & Claudication - FCB | Lecture | 0 | 0 | 0.59 | 3-00265-Ischemia, Angina & Claudication_CONTENT_GCA_25.pdf |
| 0.53 | RU | AMC | 4 | Renal Failure Pharmacology - AMC | Lecture | 0 | 0 | 0.53 | Final_Before_RenalFailurePharmZuckerman_Halmo v12052025.pptx |
- PCV wk3 Anticoagulants, Antiplatelets & Thrombolytics - AMC — Zuckerman Final AFTER Anticoagulants Antiplateletes Thrombolytics v10032025.pptx p.39: | # 38 year old develops right arm DVT. Appropriate therapy includes Heating pad with PO aspirin IV Heparin PO Warfarin with IV heparin bridge PO Warfarin with SC enoxaparin bridge Rivaroxaban
- PCV wk3 Ischemia, Angina & Claudication - AMC — M1 Event material for ischemia, angina, claudication 2025 FINAL.pptx p.54: | # Anti-thrombotic Medical Targets
Anti-platelet agents (aspirin, P2Y12 inhibitors, GP 2b/3a inhibitors) Anticoagulants (warfarin, unfractionated heparin, LMWH, direct thr - FP wk1 Case-Based Review: Pharmacogenetics - FCB — 1-00085-Case-Based Pharmacogenetics_CONTENT_GCA_25.pdf p.11: | 3 Case: polymorphisms & warfarin • A 28-year-old healthy individual presents with pain and swelling in the left lower leg. Ultrasound confirms a deep vein thrombosis, and the patient is admitted fo
Q20: How does asthma coverage progress through PCV (immunology, pharmacology, cases)?
Query asthma · scope PCV AY25-26 · gold Asthma, Allergens, Lower Airway Pharmacology, Clinical Cases: Asthma & COPD, Obstructive Lung Disease · recall@10 4/4
MeSH expansion added: Bronchial Asthma, Asthmas
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.83 | PCV | AMC | 2 | Immunology: Asthma, Allergens & Anaphylaxis - AMC | Case-Based Instruction/Learning | 1 | 0.84 | 0.99 | PCV. Asthma, Allergens & Anaphylaxis 2025_before class_FINAL.pptx |
| 2.73 | PCV | FCB | 2 | Immunology: Asthma, Allergens & Anaphylaxis - FCB | Lecture | 0.91 | 0.84 | 0.99 | 2-00150-Asthma, Allergens & Anaphylaxis_CONTENT_GCA_25-26.pdf |
| 2.44 | PCV | AMC | 2 | Overview of Obstructive Lung Disease - AMC | Lecture | 0.73 | 0.79 | 0.92 | Overview of Obstructive Lung Disease 2025 - FINAL.pptx |
| 2.38 | PCV | AMC | 2 | PCV Clinical Cases: Asthma & COPD - AMC | Case-Based Instruction/Learning | 0.68 | 0.75 | 0.94 | Clinical Cases Asthma and COPD - Student version for release before.pptx |
| 1.89 | PCV | AMC | 2 | PCV Week 2: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.89 | STUDENT GUIDE. PCV Immunology. Allergens, Asthma & Anaphylaxis.pdf |
| 1.74 | PCV | FCB | 2 | Lower Airway Pharmacology - FCB | Lecture | 0 | 0.79 | 0.95 | 2-00155-Lower Airway Pharmacology_CONTENT_GCA_25.pdf |
| 1.72 | PCV | AMC | 2 | Lower Airway Pharmacology - AMC | Large Group | 0 | 0.79 | 0.93 | Zuckerman Final AFTER PCV Lower Airway Pharm v10032025.pptx |
| 1.66 | PCV | FCB | 2 | Overview of Obstructive Lung Disease - FCB | Lecture | 0 | 0.79 | 0.87 | 2-00140-Obstructive Lung Disease_CONTENT_GCA_25-26.pdf |
| 1.64 | PCV | FCB | 1 | Pulmonary Function Testing - FCB | Lecture | 0 | 0.72 | 0.93 | 1-00025-Pulmonary Function Tests_CONTENT_GCA_25.pdf |
| 1.63 | PCV | FCB | 2 | PCV Clinical Cases: Asthma & COPD - FCB | Small Group | 0.87 | 0.75 | 0 | nan |
- PCV wk4 PCV Week 4: VISTA - AMC — Health Equity PCV Vista 2025.pptx p.22: | # Key Data Points on Asthma Mortality | Factor | FINDINGS | | — | — | | Age | Adults >6x more likely than children to die; highest among age ≥65 | | Gender | Females have higher death rates tha
- PCV wk2 Immunology: Asthma, Allergens & Anaphylaxis - AMC — PCV. Asthma, Allergens & Anaphylaxis 2025_before class_FINAL.pptx p.2: | # Learning Objectives. Immunology: Asthma, Allergens & Irritants PRE-WORK Define allergen Define asthma IN-CLASS Explain airway inflammation in asthma and allergy Describe the current understanding
- PCV wk2 Immunology: Asthma, Allergens & Anaphylaxis - FCB — 2-00150-Asthma, Allergens & Anaphylaxis_CONTENT_GCA_25-26.pdf p.29: | Q’s Question A 46-year-old individual with a history of severe persistent asthma presents for evaluation of poorly controlled symptoms despite high-dose inhaled corticosteroids and long-acting β₂-a
Q21: How much scheduled time does PCV devote to heart failure?
Query heart failure · scope PCV AY25-26 · gold Heart Failure & Cardiomyopathy, Principles of Heart Failure Treatment, Pathology Lab: Heart Failure, Heart and Respiratory Failure · recall@10 4/4
MeSH expansion added: Right Sided Heart Failure, Congestive Heart Failure, Left-Sided Heart Failure, Cardiac Failure, Left Sided Heart Failure, Heart Decompensation, Myocardial Failure, Right-Sided Heart Failure, Hearts
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.81 | PCV | FCB | 5 | Heart Failure & Cardiomyopathy - FCB | Lecture | 1 | 0.81 | 1 | FCB-PCV-Heart Failure and Cardiomyopathy-FA25-AC-FINAL.pptx |
| 2.7 | PCV | FCB | 6 | Principles of Heart Failure Treatment - FCB | Lecture | 0.96 | 0.85 | 0.89 | 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf |
| 2.61 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0.77 | 0.85 | 0.98 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 2.54 | PCV | AMC | 5 | Heart Failure & Cardiomyopathy - AMC | Case-Based Instruction/Learning | 0.8 | 0.81 | 0.93 | Heart Failure and Cardiomyopathy - FINAL 2025.pptx |
| 2.48 | PCV | AMC | 6 | Pathology Lab: Heart Failure and Cardiomyopathy - AMC | Laboratory | 0.79 | 0.71 | 0.97 | AFTER_Heart Failure and Cardiomyopathy answers.pdf |
| 2.47 | PCV | FCB | 6 | Pathology Lab: Heart Failure and Cardiomyopathy - FCB | Laboratory | 0.92 | 0.71 | 0.83 | 6-00645-Cardiomyopathy Pathology_CONTENT_GCA_25 Fixed.pdf |
| 2.46 | PCV | AMC | 6 | PCV Clinical Cases: Heart and Respiratory Failure - AMC | Case-Based Instruction/Learning | 0.89 | 0.66 | 0.91 | FINAL PCV Cases Heart and Resp Failure Week 6 2025 - with answers, release AFTER.pptx |
| 1.96 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.96 | PCV Heart failure prework w audio.pptx |
| 1.69 | PCV | AMC | 6 | PCV Week 6: Prework - AMC | Directed Independent Learning | 0 | 0.81 | 0.88 | PCV Heart failure treatments prework slides.pptx |
| 1.64 | PCV | AMC | 4 | Valvular Heart Disease - AMC | Case-Based Instruction/Learning | 0.52 | 0.43 | 0.7 | Valvular Heart Disease_2025.pptx |
- PCV wk5 Heart Failure & Cardiomyopathy - FCB — FCB-PCV-Heart Failure and Cardiomyopathy-FA25-AC-FINAL.pptx p.33: | # Consequences of Right vs. Left sided Heart Failure
 · recall@10 10 hits
MeSH expansion added: Angiotensin-Forming Enzyme, Preprorenin, Pre Prorenin, Angiotensins, Angiotensin Forming Enzyme, Inactive Renin, Pre-Prorenin, Prorenin, Big Renin
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 1.9 | RU | AMC | 2 | Extracellular Na+ & H2O - AMC | Lecture | 0 | 0.91 | 0.99 | Regulation of ECF Na and H2O_1.20.26.pptx |
| 1.88 | EM | AMC | 2 | Review of Endocrine Regulation of Kidneys - AMC | Lecture | 0 | 1 | 0.88 | Endocrine regulation of kidneys 2026BEFORECLASS.pptx |
| 1.78 | EM | FCB | 2 | Review of Endocrine Regulation of Kidneys - FCB | Lecture | 0 | 1 | 0.78 | 2-20260526_1000-Renal Endocrine Review_CONTENT_GCA_26.pdf |
| 1.76 | RU | FCB | 2 | Extracellular Na+ & H2O - FCB | Lecture | 0 | 0.91 | 0.85 | 2-00155-Extracellular Na+ & H2O_GCA_CONTENT_26.pdf |
| 1.73 | PCV | AMC | 6 | PCV Week 6: Prework - AMC | Directed Independent Learning | 0 | 0.88 | 0.86 | PCV Heart failure treatments prework slides.pptx |
| 1.57 | RU | AMC | 1 | Overview of Renal Physiology - AMC | Lecture | 0 | 0.72 | 0.86 | Renal Physiology REC 2026.pptx |
| 1.51 | RU | FCB | 1 | Overview of Renal Physiology - FCB | Lecture | 0 | 0.72 | 0.79 | 1-00020-Course Intro & Overview of Renal Physiology_GCA_CONTENT_26.pdf |
| 1.22 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0 | 0.47 | 0.76 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 1.2 | EM | AMC | 4 | Adrenal Hypofunction & Hyperfunction - AMC | Lecture | 0 | 0.32 | 0.89 | Adrenal Hypo- & HyperfunctionBEFORECLASSFINAL.pptx |
| 1.17 | EM | FCB | 4 | Adrenal Hypofunction & Hyperfunction - FCB | Lecture | 0 | 0.32 | 0.85 | FCB_EM_Adrenal Hypofunction and hyperfunction_Slides.pptx |
- FP wk3 Overview of Homeostasis - AMC — draft_Overview of Homeostasis AK 2025.pptx p.26: | Renin-Angiotensin-Aldosterone System (RAAS)
Campbell 2025 - RU wk2 Extracellular Na+ & H2O - AMC — Regulation of ECF Na and H2O_1.20.26.pptx p.25: | # Renin-Angiotensin-Aldosterone System Sodium retention Increased BP Angiotensinogen Renin Angiotensin I MR in collecting duct ACE Angiotensin II Aldosterone Adrenal Gland (Zona Glomerulosa)
- EM wk4 Adrenal Hypofunction & Hyperfunction - AMC — Adrenal Hypo- & HyperfunctionAFTERCLASSFINAL.pptx p.21: |
Aldosterone secretion is regulated by RAAS Renin ↓ Angiotensinogen Angiotensin I ↓ ACE Angiotensin II ↓ Aldosterone # Renin-Angiote
Q27: Is hypertension treatment taught in more than one course?
Query hypertension treatment antihypertensive · scope all courses AY25-26 · gold (none specified) · recall@10 10 hits
MeSH expansion added: High Blood Pressure, Treatments, Anti Hypertensive, Therapy, Anti Hypertensive Agent, Antihypertensive Drug, Anti-Hypertensives, Antihypertensive Drugs, Antihypertensives, Therapies
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.71 | RU | AMC | 2 | Anti-hypertensives & Diuretics - AMC | Lecture | 1 | 0.85 | 0.86 | SOM AntiHTN Diuretics 2026 final.pptx |
| 2.17 | RU | FCB | 2 | Secondary Causes of Hypertension - FCB | Lecture | 0.6 | 0.7 | 0.87 | 2-00195-Secondary Causes of Hypertension_GCA_CONTENT_26.pdf |
| 2.14 | RU | FCB | 3 | Small Group - Potassium Regulation & Hypertension - FCB | Small Group | 0.53 | 0.7 | 0.91 | 3-00315-K+ Regulation & Hypertension (Cases)_WITH_ANSWERS_26.pdf |
| 2.07 | RU | FCB | 2 | Anti-hypertensives & Diuretics - FCB | Lecture | 0.58 | 0.85 | 0.64 | 2-00215-Antihypertensives & Diuretics_GCA_CONTENT_26.pdf |
| 2 | RU | FCB | 2 | Hypertension - FCB | Lecture | 0.63 | 0.73 | 0.64 | 2-00190-Hypertension_GCA_CONTENT_26.pdf |
| 2 | RU | AMC | 2 | Hypertension - AMC | Lecture | 0.61 | 0.73 | 0.66 | Hypertension_Bansal_2026.pptx |
| 1.94 | RU | AMC | 2 | Secondary Causes of Hypertension - AMC | Lecture | 0.64 | 0.7 | 0.61 | Secondary_Hypertension_Bansal_2026.pptx |
| 1.74 | EM | FCB | 1 | Intro to Obesity Treatment: Counseling, Diet, Medications & Surgery - FCB | Lecture | 0.35 | 0.39 | 1 | 1-20260520_1030-Intro to Obesity Treatment_CONTENT_GCA_26.pdf |
| 1.63 | RU | AMC | 3 | Small Group - Potassium Regulation & Hypertension - AMC | Small Group | 0.53 | 0.7 | 0.4 | Pre_Potassium and HTN Small Group 2025.doc |
| 1.62 | PCV | AMC | 6 | Pulmonary Vascular Disease - AMC | Lecture | 0 | 1 | 0.62 | Pulmonary Vascular Disease 2025.pptx |
- EM wk1 Intro to Obesity Treatment: Counseling, Diet, Medications & Surgery - FCB — 1-20260520_1030-Intro to Obesity Treatment_CONTENT_GCA_26.pdf p.41: | Q’s Question A 41-year-old individual with obesity and poorly controlled hypertension is being considered for pharmacologic weight loss therapy. Blood pressure is 168/98 mm Hg despite antihypertens
- RU wk1 Overview of Renal Physiology - FCB — RU_BONUS_Practice Qustions_03_GCA_26.pdf p.21: | Question A 55-year-old individual presents to the clinic for evaluation of resistant hypertension. Despite adherence to three antihypertensive medications, including a diuretic, their blood pressur
- RU wk3 Small Group - Potassium Regulation & Hypertension - FCB — 3-00315-K+ Regulation & Hypertension (Cases)_WITH_ANSWERS_26.pdf p.3: | LEARNING OBJECTIVE HELPER 1.1 AHA guideline-based initial antihypertensive therapy selection: Apply a guideline-consistent approach to initial pharmacologic therapy for hypertension based on blood
Q28: Where is beta-blocker pharmacology taught?
Query beta blocker · scope all courses AY25-26 · gold Autonomic Regulation, Antidysrhythmics, Heart Failure Treatment, Ischemia · recall@10 4/4
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 1.94 | PCV | FCB | 3 | Acute Coronary Syndromes - Diagnosis & Management - FCB | Lecture | 0 | 1 | 0.94 | 3-00300-Acute Coronary Syndromes_CONTENT_GCA_25.pdf |
| 1.86 | PCV | FCB | 6 | Principles of Heart Failure Treatment - FCB | Lecture | 0 | 0.88 | 0.98 | 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf |
| 1.85 | PCV | AMC | 3 | Acute Coronary Syndromes - Diagnosis & Management - AMC | Large Group | 0 | 1 | 0.85 | Acute Coronary Syndromes Part 2 Bricker - Complications and Management 2025.pptx |
| 1.78 | PCV | AMC | 2 | ECG Cases: Cardiac Dysrhythmias - AMC | Case-Based Instruction/Learning | 0 | 0.86 | 0.92 | Cardiac Dysrhythmias Clin Cases 2025 Answers version.pptx |
| 1.59 | PCV | AMC | 6 | Principles of Heart Failure Treatment - AMC | Lecture | 0 | 0.88 | 0.71 | Principles of Heart Failure Treatment - 2025 FINAL.pptx |
| 1.49 | PCV | FCB | 3 | Ischemia, Angina & Claudication - FCB | Lecture | 0 | 0.57 | 0.92 | 3-00265-Ischemia, Angina & Claudication_CONTENT_GCA_25.pdf |
| 1.4 | PCV | AMC | 2 | Pharmacology of Antidysrhythmics - AMC | Lecture | 0 | 0.47 | 0.93 | Draft_Before_Antidysrythmic_09192025.pptx |
| 1.31 | PCV | FCB | 2 | Pharmacology of Antidysrhythmics - FCB | Lecture | 0 | 0.47 | 0.84 | 2-00180-Pharmacology of Antiarrhythmic Drugs_CONTENT_GCA_25.pdf |
| 1.09 | PCV | FCB | 2 | Autonomic Regulation of the Cardiovascular System - FCB | Lecture | 0 | 0.34 | 0.75 | 2-00145-Autonomic CV Regulation_CONTENT_GCA_25.pdf |
| 1 | RU | AMC | 2 | Anti-hypertensives & Diuretics - AMC | Lecture | 0 | 0 | 1 | SOM AntiHTN Diuretics 2026 final.pptx |
- RU wk2 Anti-hypertensives & Diuretics - AMC — SOM AntiHTN Diuretics 2026 final.pptx p.63: | # Beta Receptors
https://www.cvpharmacology.com/cardioinhibitory/beta-blockers - RU wk2 Regulation of Extracellular K+ - AMC — Potassium Regulation2026.pptx p.11: | Factors that lead to Extracellular Shifting of Potassium Non-selective Beta blockers 2 K+ ATP 3 Na+ [K+] B2 Beta blockers
- PCV wk
Principles of Heart Failure Treatment - FCB — 6-00630-Principles of Heart Failure Treatment_CONTENT_GCA_25 Fixed.pdf p.68: | C Case 6: Beta-blocker initiation in stable chronic HF A 58-year-old with stable HFrEF is ready for beta-blocker therapy after euvolemia is achieved. Why it matters clinically: Beta-blockers reduce
Q29: What changed in the Acute Coronary Syndromes session between AY24-25 and AY25-26?
Query acute coronary syndrome · scope PCV AY25-26 · gold Acute Coronary Syndromes · recall@10 1/1
MeSH expansion added: Symptom Clusters, Syndromes, Acute Coronary Syndromes, Symptom Cluster
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.98 | PCV | AMC | 3 | Acute Coronary Syndromes - Diagnosis & Management - AMC | Large Group | 0.98 | 1 | 1 | Acute Coronary Syndromes Part 1 Bricker - Diagnosis 2025.pptx |
| 2.93 | PCV | FCB | 3 | Acute Coronary Syndromes - Diagnosis & Management - FCB | Lecture | 1 | 1 | 0.93 | 3-00300-Acute Coronary Syndromes_CONTENT_GCA_25.pdf |
| 1.95 | PCV | AMC | 3 | Ischemia, Angina & Claudication - AMC | Case-Based Instruction/Learning | 0 | 1 | 0.95 | M1 Event material for ischemia, angina, claudication 2025 FINAL.pptx |
| 1.92 | PCV | FCB | 3 | Ischemia, Angina & Claudication - FCB | Lecture | 0 | 1 | 0.92 | 3-00265-Ischemia, Angina & Claudication_CONTENT_GCA_25.pdf |
| 1.26 | PCV | AMC | 3 | PCV Anatomy Lab 8: Coronary & Peripheral Circulation, Thoracic Innervation - AMC | Laboratory | 0.38 | 0.41 | 0.47 | DRAFT_before_PCV Wk3 Anatomy Lab #8_AY25-26.pptx |
| 1.24 | PCV | FCB | 3 | PCV Anatomy Lab 8: Coronary & Peripheral Circulation, Thoracic Innervation - FCB | Laboratory | 0.35 | 0.41 | 0.48 | 11-17-25 FCB-PCV-Gross Anatomy Lab Coronary & Peripheral Circulation, Thoracic Innervation.pptx |
| 1.22 | PCV | FCB | 3 | Pathology Lab: Pathology of Atherosclerosis, Ischemia & Infarction - FCB | Small Group | 0 | 0.29 | 0.93 | 3-00275-Ischemia & Infarction Path_CONTENT_GCA_25.pdf |
| 1.13 | PCV | FCB | 1 | Cardiac Conduction & ECG Intro - FCB | Lecture | 0 | 0.55 | 0.58 | 1-00060-Cardiac Conduction & ECG Intro_CONTENT_GCA_25.pdf |
| 1.1 | PCV | AMC | 3 | Pathology Lab: Pathology of Atherosclerosis, Ischemia & Infarction - AMC | Small Group | 0 | 0.29 | 0.81 | Atherosclerosis, Ischemia and Infarction Facilitator slides with notes pages.pdf |
| 1.06 | PCV | AMC | 1 | Cardiac Conduction & ECG Intro - AMC | Lecture | 0 | 0.55 | 0.51 | Cardiac conduction and ECG intro 2025 FINAL.pptx |
- PCV wk3 Acute Coronary Syndromes - Diagnosis & Management - AMC — Acute Coronary Syndromes Part 1 Bricker - Diagnosis 2025.pptx p.2: | # Learning Objectives Discuss the pathophysiology of acute coronary syndromes, how different types of acute coronary syndromes (unstable angina, non-ST-elevation MI, and ST-elevation MI) differ fro
- PCV wk3 Ischemia, Angina & Claudication - AMC — M1 Event material for ischemia, angina, claudication 2025 FINAL.pptx p.46: | # Acute Coronary Syndromes and Acute Limb Ischemia: Definitions Acute coronary syndrome (ACS) = combination of chest discomfort at rest, ECG changes, and / or biomarker elevation Acute limb ischemi
- PCV wk3 Acute Coronary Syndromes - Diagnosis & Management - FCB — 3-00300-Acute Coronary Syndromes_CONTENT_GCA_25.pdf p.17: | 1 7 Acute coronary syndrome
Q30: How different are AMC and FCB materials for the Tuberculosis session?
Query tuberculosis · scope PCV AY25-26 · gold Tuberculosis · recall@10 1/1
MeSH expansion added: Koch Disease, Kochs Disease, Mycobacterium tuberculosis Infection, Mycobacterium tuberculosis Infections, Tuberculoses, Koch’s Disease
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.93 | PCV | FCB | 5 | Tuberculosis - FCB | Lecture | 1 | 0.95 | 0.99 | Tuberculosis (2025) - posted.pptx |
| 2.57 | PCV | AMC | 5 | Tuberculosis - AMC | Lecture | 0.62 | 0.95 | 1 | tuberculosis 2025.pptx |
| 1.69 | PCV | AMC | 5 | PCV Week 5: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.69 | PCV CT Chest Prework w audio 2024.pptx |
| 1 | PCV | FCB | 5 | PCV Week 5: Prework - FCB | Directed Independent Learning | 0 | 1 | 0 | nan |
| 0.96 | PCV | AMC | 4 | Immunology: Pulmonary Host Defense - AMC | Large Group | 0 | 0 | 0.96 | PCV. Pulmonary Host Defense 2025_before class_FINAL.pptx |
| 0.83 | PCV | AMC | 4 | Microbiology of Lung Infections: Bacterial Pneumonia - AMC | Lecture | 0 | 0 | 0.83 | Bacterial Pneumonia Janoff 2025.pptx |
| 0.81 | PCV | AMC | 5 | Pathology Lab: Histology & Pathology of Thoracic Malignancy & Benign Nodular Lesions - AMC | Case-Based Instruction/Learning | 0 | 0 | 0.81 | AFTER_Thoracic Malignancy and Benign Nodular Lesions answers.pdf |
| 0.8 | PCV | AMC | 5 | Pathologic Findings on CT Scans - AMC | Lecture | 0 | 0 | 0.8 | Pathologic findings on CT 2025 FINAL.pptx |
| 0.8 | PCV | FCB | 5 | Pathologic Findings on CT Scans - FCB | Lecture | 0 | 0 | 0.8 | Pathologic findings on CT 2025 FINAL.pptx |
| 0.77 | PCV | AMC | 6 | Pathology Lab: Heart Failure and Cardiomyopathy - AMC | Laboratory | 0 | 0 | 0.77 | AFTER_Heart Failure and Cardiomyopathy answers.pdf |
- PCV wk5 Tuberculosis - AMC — tuberculosis 2025.pptx p.2: | # Learning Objectives Differentiate between the clinical features of and diagnostic studies for latent and reactivation TB. Discuss the epidemiology, microbiology and pathogenesis of M. tuberculosi
- PCV wk5 Tuberculosis - FCB — Tuberculosis (2025) - posted.pptx p.2: | # Learning Objectives List common infectious causes of hemoptysis. Differentiate between the clinical features of and diagnostic studies for latent and reactivation TB. Discuss the epidemiology, mi
- PCV wk4 Immunology: Pulmonary Host Defense - AMC — PCV. Pulmonary Host Defense 2025_before class_FINAL.pptx p.32: | TUBERCULOSIS
A few EXAMPLES of ONE-PAGE VISUALS ABOUT TB
https://andrecaetano.com/portfolio/voyages-in-tuberculosis/ https://www.behance.net/ga
Q31: I’m writing a new session on pulmonary hypertension. What already exists (objectives, sessions, prerequisites)?
Query pulmonary hypertension · scope all courses AY25-26 · gold Pulmonary Vascular Disease · recall@10 1/1
MeSH expansion added: High Blood Pressure, High Blood Pressures
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 2.73 | PCV | FCB | 6 | Pulmonary Vascular Disease - FCB | Lecture | 0.73 | 1 | 1 | 6-00635-Pulmonary Vascular Disease_CONTENT_GCA_25 Fixed.pdf |
| 2.55 | PCV | AMC | 6 | Pulmonary Vascular Disease - AMC | Lecture | 0.61 | 1 | 0.93 | Pulmonary Vascular Disease 2025.pptx |
| 2.24 | RU | FCB | 2 | Hypertension - FCB | Lecture | 0.99 | 0.68 | 0.57 | 2-00190-Hypertension_GCA_CONTENT_26.pdf |
| 2.23 | RU | AMC | 2 | Secondary Causes of Hypertension - AMC | Lecture | 1 | 0.63 | 0.59 | Secondary_Hypertension_Bansal_2026.pptx |
| 2.17 | RU | AMC | 2 | Hypertension - AMC | Lecture | 0.96 | 0.68 | 0.54 | Hypertension_Bansal_2026.pptx |
| 2.04 | RU | FCB | 2 | Secondary Causes of Hypertension - FCB | Lecture | 0.95 | 0.63 | 0.45 | 2-00195-Secondary Causes of Hypertension_GCA_CONTENT_26.pdf |
| 1.99 | PCV | AMC | 5 | Immunology: Autoimmune Lung Disease, Sinus Disease & Hemorrhage - AMC | Large Group | 0.51 | 0.54 | 0.94 | PCV. Autoimmune Lung Disease 2025_before class_FINAL.pptx |
| 1.98 | PCV | FCB | 1 | Pulmonary + Systemic Circulation - FCB | Lecture | 0.73 | 0.59 | 0.66 | FCB-PCV-Circulatory Physiology-FA25-AC.pptx |
| 1.96 | PCV | AMC | 1 | Pulmonary + Systemic Circulation - AMC | Lecture | 0.69 | 0.59 | 0.68 | Circulation talk 2025.pptx |
| 1.91 | RU | FCB | 3 | Small Group - Potassium Regulation & Hypertension - FCB | Small Group | 0.83 | 0.6 | 0.47 | 3-00315-K+ Regulation & Hypertension (Cases)_WITH_ANSWERS_26.pdf |
- PCV wk
Pulmonary Vascular Disease - FCB — 6-00635-Pulmonary Vascular Disease_CONTENT_GCA_25 Fixed.pdf p.39: | Q’s Question A 59-year-old individual presents with progressive dyspnea and lower-extremity edema. Echocardiography shows elevated right ventricular systolic pressure and mild right ventricular enl - PCV wk6 Pulmonary Vascular Disease - FCB — 6-00635-Pulmonary Vascular Disease_CONTENT_GCA_25.pdf p.39: | Q’s Question A 59-year-old individual presents with progressive dyspnea and lower-extremity edema. Echocardiography shows elevated right ventricular systolic pressure and mild right ventricular enl
- PCV wk1 Normal Lung Histology & Pathology of Impaired Gas Exchange - AMC — AFTER_Normal lung histology and pathology of gas exchange answers.pdf p.31: | Q4. How does pulmonary fibrosis reduce A) Normal Reference Pulmonary Arteriole B) Pulmonary hypertension ventilation and oxygenation? Patients with pulmonary fibrosis can also develop increased pre
Q32: What have students already learned about acid-base physiology before the PCV blood gas session?
Query acid base · scope all courses AY25-26 · gold (none specified) · recall@10 10 hits
MeSH expansion added: Acids
| score | course | campus | week | event_title | method | title | objective | material | top_file |
|---|---|---|---|---|---|---|---|---|---|
| 3 | RU | AMC | 2 | Acid Base Disorders - AMC | Lecture | 1 | 1 | 1 | Final_Clinical Acid Base_Bansal_2026.pptx |
| 2.9 | RU | FCB | 2 | Acid Base Disorders - FCB | Lecture | 0.97 | 1 | 0.93 | 2-00170-Acid Base Disorders_GCA_CONTENT_26.pdf |
| 2.52 | RU | AMC | 2 | Role of Kidney in Acid Base Balance - AMC | Lecture | 0.96 | 0.59 | 0.97 | Final_Kidney in acid base_Bansal_2026.pptx |
| 2.41 | RU | FCB | 2 | Role of Kidney in Acid Base Balance - FCB | Lecture | 0.89 | 0.59 | 0.93 | 2-00165-Role of Kidney in Acid Base Balance_GCA_CONTENT_26.pdf |
| 1.97 | RU | AMC | 3 | RU Week 3: Prework - AMC | Directed Independent Learning | 0 | 1 | 0.97 | Pre_Acid Base Small Groups 2025 (2) (1) (1).doc |
| 1.89 | RU | AMC | 3 | Small Group - Acid/Base Pathophysiology - AMC | Small Group | 0.92 | 0 | 0.97 | Pre_Acid Base Small Groups 2025.doc |
| 1.86 | FP | AMC | 3 | Overview of Homeostasis - AMC | Lecture | 0.5 | 0.66 | 0.7 | draft_Overview of Homeostasis AK 2025.pptx |
| 1.82 | RU | FCB | 3 | Small Group - Acid/Base Pathophysiology - FCB | Small Group | 0.89 | 0 | 0.93 | 3-00305-Acid-Base Pathophysiology (Cases)_NO_ANSWERS_26.pdf |
| 1.7 | PCV | AMC | 1 | PCV Clinical Cases: ABG, PFT, ECG - AMC | Case-Based Instruction/Learning | 0 | 0.77 | 0.92 | Clinical Cases ABG-PFT-ECG 2025 - release to students AFTER event.pptx |
| 1.69 | RU | AMC | 3 | Acid/Base Cases Pathophysiology - AMC | nan | 0.75 | 0.95 | 0 | nan |
- RU wk2 Acid Base Disorders - AMC — Final_Clinical Acid Base_Bansal_2026.pptx p.22: | What is the second acid-base disorder ? | Primary Acid Base Disorder | How to Identify Second Acid Base Disorder? | Second Acid Base Disorder | | — | — | — | | Respiratory Alkalosis OR Respir
- RU wk2 Role of Kidney in Acid Base Balance - AMC — Final_Kidney in acid base_Bansal_2026.pptx p.43: | # Summary – Acid-Base Balance Renally secreted H+ must be buffered in urine Titratable acid Ammonia trapping Renal handling of acid is regulated by ECF pH and CO2 Transporters for H+ and HCO3- are
- PCV wk1 Blood Gas Analysis: Gas Exchange & Respiratory Failure - AMC — A Practical Clinical Approach to the Analysis of Acid-Base Disorders and Respiratory Failure v2.2 - HIGHLY OPTIONAL.pdf p.5: | NORMAL ACID BASE PHYSIOLOGY Before discussing acid-base and respiratory derangements, let’s review some normal physiology. The respiratory and renal systems are the primary regulators of acid-base